QHSLab, Inc. (USAQ)
QHSLab, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in West Palm Beach, FL, US. The stock last traded at $0.35, up 0.00% on the session, giving a market capitalisation of $5.3M. On trailing twelve-month figures it carries a trailing P/E of 7.38, a net margin of 17.4%. Its beta of 0.60 implies it has historically moved less than the broad market.
QHSLab, Inc. is a company operating in the medical technology and Software-as-a-Service (SaaS) sectors. Its core focus is on advancing value-based healthcare, medical informatics, and personalized medicine driven by algorithms. The firm also develops digital therapeutic solutions and on-site technologies intended for remote patient oversight, the management of chronic conditions, and proactive health maintenance. Among its offerings is a proprietary cloud-based SaaS platform, also known as QHSLab (Quality Health Score Lab expert system). This system empowers physicians and healthcare organizations to securely record and store electronic patient data. Additionally, QHSLab, Inc. acts as a distributor, providing primary care physicians with AllergiEnd, a product line encompassing diagnostic tools and allergen immunotherapy treatments. All of its solutions are strategically designed to aid in the prevention, early identification, effective management, and potential reversal of chronic diseases. The company was established in 1983 and is headquartered in West Palm Beach, Florida. It operated under the name USA Equities Corp. until April 2022, when it officially rebranded to QHSLab, Inc. The company also maintains a strategic partnership with Medical License Factory, LLC.
QHSLab, Inc. is most often compared with the following Healthcare names: